Evidence map›Paper›PMID 31291010›Full record

ArticleCancer2019

Intent and subsequent initiation of human papillomavirus vaccine among young cancer survivors.

Brooke Cherven, Sharon M Castellino, Yanjun Chen, F Lennie Wong, Jocelyn M York, Karen Wasilewski-Masker, Melissa M Hudson, Smita Bhatia, James L Klosky, Wendy Landier

Abstract read
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Brooke ChervenSchool of Nursing, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0002-5978-655X
Sharon M CastellinoEmory University and Children's Healthcare of Atlanta, Atlanta, Georgia.
Yanjun ChenInstitute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
F Lennie WongCity of Hope, Duarte, California.
Jocelyn M YorkInstitute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Karen Wasilewski-MaskerEmory University and Children's Healthcare of Atlanta, Atlanta, Georgia.
Melissa M HudsonSt. Jude Children's Research Hospital, Memphis, Tennessee.
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0002-7755-5683
James L KloskyEmory University and Children's Healthcare of Atlanta, Atlanta, Georgia.
Wendy LandierSchool of Nursing, University of Alabama at Birmingham, Birmingham, Alabama.

Funding

Quadrivalent Human Papillomavirus (HPV) Vaccine in Cancer SurvivorsR01CA166559 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KLOSKY, JAMES, LANDIER, WENDY · 2012 to 2016
$3.0M
American Cancer Society 17-078-01-SCNMerck Sharp and Dohme MISP #40083NCI NIH HHS R01 CA166559NCI NIH HHS R01CA166559Robert Wood Johnson Foundation RWJF 72509
6 · The paper itself

Abstract

backgroundDespite an increased risk of subsequent human papillomavirus (HPV)-related malignancies, HPV vaccine initiation rates among cancer survivors remain critically low. The purpose of this study was to determine the relationship between HPV vaccine intent and subsequent vaccine initiation among cancer survivors by linking data from a cross-sectional survey with state-based immunization registry records.

methodsCancer survivors who were 9 to 26 years old were surveyed 1 to 5 years after their treatment to assess their HPV vaccine initiation status, HPV vaccine intent, sociodemographic factors, and vaccine-related health beliefs. HPV vaccine doses/dates were abstracted from the Georgia Registry for Immunization Transactions for 3.5 years after survey participation. Logistic regression models identified factors associated with vaccine intent and subsequent vaccine initiation.

resultsAmong survivors who were HPV vaccine-naive at survey participation (n = 103), factors associated with vaccine intent included the following: 1) provider recommendation for the HPV vaccine (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.4-18.1; P = .014), 2) positive general attitude toward vaccines (OR, 4.8; 95% CI, 2.0-11.2; P < .001), and 3) perceived severity of HPV disease (OR, 3.5; 95% CI, 1.2-9.9; P = .02). Of the vaccine-naive patients, 28 initiated the HPV vaccine at a median of 1.1 years after the survey. Initiation was more likely among survivors who had reported vaccine intent (OR, 3.9; 95% CI, 1.2-12.5; P = .02) and was less likely among older survivors (OR per year, 0.7; 95% CI, 0.6-0.9; P < .001).

conclusionsThese findings suggest that provider recommendation for the HPV vaccine plays a role in establishing intent, which then translates into subsequent initiation.

Indexed as

Cancer SurvivorsAdolescentAdultChildChild, PreschoolCross-Sectional StudiesFemaleHealth Knowledge, Attitudes, PracticeHumansMalePapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesSurveys and QuestionnairesVaccinationYoung AdultPapillomavirus Vaccinesadolescentcancer survivorspapillomavirus vaccinesyoung adult

Identifiers

PMID31291010
PMCPMC7427343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.